Croatia’s JGL expands to Uzbekistan

The expansion is part of the company’s expansion strategy and JGL enters Uzbekistan with a portfolio of its key groups of therapeutic products for flu and common cold, ophthalmology and dermatology.

"It is a market that is growing and opening to the world," the head of market operations at JGL, Alenka Jajac-Knez, said.

Uzbekistan has a population of 36 million which will increase to almost 41 million by 2040, Jajac-Knez said, adding that the Central Asian economy is expected to grow by 10% in the next couple of years, while inflation is expected to fall.

Uzbekistan's drug market, estimated at $1.6 billion ($1.5 billion), has been recently expanding by 6.5% a year, while market of groups of therapeutic groups manufactured by JGL has been growing in double digits, she said.

Founded in 1991, JGL is one of the largest drug makers in Croatia, specialised in the production of sterile nose, eye and ear drop solutions.

($ = 0.931 euro)